Monthly Update Central & Peripheral Nervous Systems: Nefazodone - a summary of the available data on a new antidepressant agent

References

• ANONYMOUS: First launch for BMS' nefazodone. Scrip (September 9, 1994) 1956: 22.
   Google Scholar
• ANONYMOUS: Bristol-Myers Squibb's serzone (nefazo-done) works in treating depression, FDA advisory Com-mittee concludes, but effective dose remains unclear. FDC Reports - The Pink Sheet (July 26, 1993) 55(30):17–18.
   Google Scholar
• ANONYMOUS: Bristol-Myers Squibb's serzone. FDC Re-ports - The Pink Sheet (November 14, 1994) 56(46):backpage.
   Google Scholar
• ANONYMOUS: Bristol-Myers Squibb's serzone has com-plementary actions on serotonin; may provide benefi-cial effects on sleep, sexual function, anxiety - approvaL FDC Reports - The Pink Sheet (January 2, 1995) 57(1):11–12.
   Google Scholar
• EISON AS, EISON MS, TORRENTE JR, WRIGHT RN, YOCCA FD: Nefazodone: Preclinical pharmacology of a new antidepressant. Psychopharm. Bull. (1990) 26(3):311–315. A summary of much of the preclinical pharmacology data that are available on nefazodone.
   Google Scholar
• HUMPHREY PPA, HARTIG P, HOYER D: A proposed newnomenclature for 5-HT receptors. Trends Pharm. Sci. (1993) 14:233–236.
   PubMed Web of Science ®Google Scholar
• HOYER D, CLARICE DE, FOZARD JR, HARTIG PR, MARTIN GR, MYLECHARANE EJ, SAXENA PR, HUMPHREY PPA: International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharm. Rev. (1994) 46(2):157–203.
   PubMed Web of Science ®Google Scholar
• A thorough review of the current nomenclature for serotonin receptors. Lists of agonists and antagonists for various serotonin receptor subtypes are also included.
   Google Scholar
• BOLDEN-WATSON C, RICHELSON E: Blockade by newly-developed antidepressants of biogenic amine uptake Into rat brain synaptosomes. Life Sci. (1993) 52(12):1023–1029.
   PubMed Web of Science ®Google Scholar
• TAYLOR DP, EISON MS, RIBLET LA, TEMPLE DL, YEVICHJP, SMITH DW: Selective 5-HT2 receptor blockade: Phar-macologic studies of MJ 13754, a nontricyclic antide-pressant candidate. Soc. Neurosci. Abstr. (1982) 8:465 (Abstract No. 128.12).
   Google Scholar
• HYSLOP DK, ALLEN LE, TAYLOR DP: Triazolo antidepres-sants do not inhibit monoamine oxidase. Drug Dev. Res. (1988) 12:77–79–
   Google Scholar
• VANDERMAELEN CP, BRASELTON JP: Effects of the anti-depressant compound nefazodone on central monoaminergic neuronal discharge in rats. Drug Dev. Res. (1992) 25:235–247.
   Web of Science ®Google Scholar
• HEMRICK-LUECKE SK, SNODDY HD, FULLER RW: Evalu-ation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci. (1994) 55(7):479–483.
   PubMed Web of Science ®Google Scholar
• SCOTT JA, CREWS FT: Down-regulation of serotonin2, but not of beta-acirenergic receptors during chronic treatment with amitriptyline is independent of stimu-lation of serotortin2 and beta-adrenergk receptors. Neuropharmacology (1986) 25(12):1301–1306.
   PubMedGoogle Scholar
• SMITH DW, EISON MS, RIBLET LA, TAYLOR DP, YEVICH JP, TEMPLE DL: Analgesic properties of MJ 13754, a nontricyclic antidepressant candidate. Soc. Neurosci. Abstr. (1983) 9:427 (Abstract No. 126.2).
   Google Scholar
• PICK CG, PAUL D, EISON MS, PASTERNAK GW: Potentia-tion of opioid analgesia by the antidepressant nefazo-done. Eur. J. Pharmacol. (1992) 211:375–381.
   PubMed Web of Science ®Google Scholar
• GOLD LH, BALSTER RL: Evaluation of nefazodone self-administration in rhesus monkeys. DrugAlcohol Depend. (1991) 28:241–247.
   PubMed Web of Science ®Google Scholar
• CURZON G, KENNETT GA: m-CPP: a tool for studyingbehavioral responses associated with 5-HT1C recep-tors. Trends Pharm. Sci. (1990) 11:181–182.
   PubMed Web of Science ®Google Scholar
• AULAKH CS, HILL JL, MURPHY DL: Effects of variousserotonin receptor subtype-selective antagonists alone and on m-chlorophenylpiperazine-induced neuroen-docrine changes in rats. J. Pharm. Exp. Ther. (1992) 263(2):588–595.
   PubMed Web of Science ®Google Scholar
• TAYLOR DP, EISON MS, HYSLOP DK, SMITH DW, YOCCAFD: Pharmacologic studies on the a-hydroxy metabolite of the potential antidepressant nefazodone. Soc. Neuro-sci. Abstr. (1986) 12:474 (Abstract No. 130.5).
   Google Scholar
• SHUKLA UA, MARATHE PH, PITTMAN KA, BARBHAIYA RH:Pharrnacokinetics, absolute bioavailability, and dispo-sition of ["CJ nefazodone in the dog. Drug Metab. Disp. (1993) 21(3):502–507.
   PubMed Web of Science ®Google Scholar
• SHUKLA UA, MARATHE PH, LABUDDE JA, PITTMAN KA,BARBHAIYA RH: Pharmacokinetics of nefazodone in the dog following single oral administration. Eur. J Metab. Pharm. (1992) 17(4):301–308.
   Web of Science ®Google Scholar
• SHUKLA UA, KAUL S, MAFtATHE PH, PITTMAN KA, BARBHAIYA RH: Pharmacokinetics of nefazodone fol-lowing multiple escalating oral doses in the dog. Eur. J. Drug Metab. Pharm. (1992) 17(4):309–318.
   PubMed Web of Science ®Google Scholar
• MAYOL RF, COLE CA, LUKE GM, COLSON ICL, KERNS EH:Characterisation of the metabolites of the antidepres-sant drug nefazodone in human urine and plasma. Drug Metab. Disp. (1994) 22:304–311.
   PubMedGoogle Scholar
• SHEA JP: Single dose pharmacokinetics of nefazodoneIn elderly subjects, renally impaired patients, and pa-tients with hepatic cirrhosis in comparison to healthy volunteers. UM. Pharmacol. Ther. (1988) 43(2):146 (Ab-stract No. PIIA–5).
   Google Scholar
• SALAZAR DE, CHAIKIN PC, SWANSON BN, RAYMOND RH:The effects of nefazodone and fiuoxetine on platelet serotonin uptake and whole blood serotonin. ClM. Pbarmacol. Ther. (1994) 55(2):137 (Abstract No. PI–55).
   Google Scholar
• GREEN DS, DOCICENS RC, SALAZAR DE, BARBHAIYA RH:Coadministration of nefazodone (Nef) and ben-zodiazepines L Pharmacokinetic assessment. Clin. Pbarmacol. Ther. (1994) 55(2):141 (Abstract No. P1–74).
   Google Scholar
• KROBOTH P, FOLAN M, LUSH R, CHAIKIN PC, BARBHAIYA RH, SALAZAR DE: Coadministration of nefazodone and benzodiazepinesPharmacodynamic assessment.Pharmacol. Ther. (1994) 55(2):142 (Abstract No. PI–75).
   Google Scholar
• DOCKENS R, SHUKLA U, ROBERTS D, GREENE D, BARBHAIYA R: A placebo controlled crossover study of the effect of nefazodone on the pharmacokinetic and pharmacodynamic responses to theophylline in pa-tients with chronic obstructive pulmonary disease (COPD). Pharm. Res. (1993) 10(Suppl.):S-353 (Abstract No. PPDM 8218).
   Google Scholar
• FEIGHNER JP, PAMBAKIAN R, FOWLER RC, BOYER WF,D'AMICO MF: A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depres-sion. Psychopharmacol. Bull. (1989) 25(2):219–221.
   PubMed Web of Science ®Google Scholar
• HAMILTON M: Development of a rating scale for primarydepressive illness. Br. J. Soc. Clin. Psychol. (1967) 6:278–296.
   PubMed Web of Science ®Google Scholar
• D'AMICO MF, ROBERTS DL, ROBINSON DS, SCHWIDERSKIUE, COPP J: Placebo-controlled dose-ranging trial de-signs in phase /I development of nefaaodone. Psycho-pharmacol. Bull. (1990) 26(1):147–150.
   PubMed Web of Science ®Google Scholar
• SPITZER RL, ENDICOTT J, ROBBINS E: Research diagnos-tic criteria: Rationale and reliability. Arch. Gen. Psychia-try (1978) 35:773–782.
   PubMed Web of Science ®Google Scholar
• ANSSEAU M, DARIMONT P, LECOQ A, DE NAYER A, EVRAD J, KREMER P, DEVOITILLE J, DIERICK M, MERTENS C, MESOTTEN F, MIREL J, TROISFONTAINES B, VAN MOF-FAERT M, VANBRABANT E: Controlled comparison of nefazodone and arnItriptyline in major depressive in-patients. Psychopharmacology (1994) 115:254–260.
   PubMedGoogle Scholar
• MONTGOMERY A, ASBERG M: A new depressive scale designed to be sensitive to change. Br.J. Psych iatry(1979) 134:382–389.
   PubMed Web of Science ®Google Scholar
• FONTAINE R, ONTIVEROS A, ELIE R, KENSLER TT, ROBERTS DL, KAPLITA S, ECKER JA, FALUDI G: A double-blind comparison of nefazodone, imipramine, and pla-cebo in major depression. J. din. Psychiatry (1994) 55:234–241.
   Google Scholar
• Results of a single centre trial comparing the efficacy of two different dose ranges of nefazodone to imipramine and placebo.
   Google Scholar
• HAMILTON M: A rating scale for depression. Neurol. Neurosurg. Psychiatry (1960) 23:56–62.
   PubMed Web of Science ®Google Scholar
• RICICELS K, SCHWEIZER E, CLARY C, FOX I, WEISE C: Nefazodone and imipramine in major depression: A placebo-controlled triaL Br. J. Psychiatry (1994) 164:802–805.
   PubMed Web of Science ®Google Scholar
• Results of a mukicentre trial comparing the efficacy of nefazodone, imipramine, and placebo in major depressive disorder.
   Google Scholar
• VOGEL GW, BUF'FENSTEIN A, MINTER K, HENNESSEY A: Drug effects on REM sleep and on endogenous depres-sion. Neurosci. Biobehav. Rev. (1990) 14:49–63.
   PubMedGoogle Scholar
• SHARPLEY AL, WALSH AES, COWEN PJ: Nefazodone a novel antidepressant may increase REM sleep. Biol. Psychiatry (1992) 31:1070–1073.
   PubMed Web of Science ®Google Scholar
• WARE JC, ROSE FV, MCBRAYER RH: The acute effects of nefazodone, trazodone and buspirone on sleep and sleep-related penile tumescence in normal subjects. Sleep (1994) 17(6):544–550.
   PubMed Web of Science ®Google Scholar
• ARMITAGE R, RUSH AJ, TRIVEDI M, CAIN J, ROFFWARG HP: The effects of nefazodone on sleep architecture in depression. Neuropsychopharmacology (1994) 10(2):123–127.
   PubMed Web of Science ®Google Scholar
• FREEMAN EW, RICKELS K, SONDHEIMER SJ, DENIS A, PFEIFER S, WEIL S: Nefazodone in the treatment of premenstrual syndrome: A preliminary study. J. Clin. Psychopharmacol. (1994) 14(3):180–186.
   PubMed Web of Science ®Google Scholar
• WALSH AES, HOCKNEY RA, CAMPLING G, COWEN PJ: Neuroendocrine and temperature effects of nefazodone in healthy volunteers. Biol. Psychiatry (1993) 33:115–119.
   PubMed Web of Science ®Google Scholar
• ALOI JA, INSEL TR, MUELLER EA, MURPHY DL: Neuroen-docrine and behavioural effects of m-chlo-rophenylpiperazine administration in rhesus monkeys. Life Sci, (1984) 34:1325–1331.
   PubMedGoogle Scholar
• MUELLER EA, MURPHY DL, SUNDERLAND T: Neuroendo-crine effects of m-chlorophenylpiperazine, a serotonin agonist, in humans. J. Clin. Endocrinol. Metab. (1985) 61:1179–1184.
   PubMed Web of Science ®Google Scholar
• WOZNIAK KM, AULAICH CS, HILL JL, MURPHY DL: Hyper-thermia induced lby mCPP in the rat and its modification by antidepressant treatments. Psychopharmacology (1989) 97:269–274.
   PubMed Web of Science ®Google Scholar
• WALSH AES, COWEN PJ: Attenuation of the prolactin-stimulating and hyperthermic effects of nefazodone after subacute treatment./ Clin. Psychopharmacol. (1994) 14(4):268–273.
   Google Scholar
• FONTAINE R: Novel serotonergic merh2nisms and clini-cal experience with nefazodone. Clin. Neuropharmacol. (1993) 16\(Suppl. 3):S45–S50.
   Google Scholar
• Contains a summary of pooled safety data from placebo-controlled trials with nefazodone.
   Google Scholar
• SUSSMAN N: The potential benefits of serotonin recep-tor-specific agents. J. din. Psychiatry (1994) 55(2):45–51.
   Google Scholar
• BREUEL HP, DE LEENHEER I, CONINX L, GAMMANS R: Comparison of the cardiovascular effects of nefazo-done, imipramine and placebo in healthy elderly vol-unteers. Eur. Neuropsychopharmacol. (1993) 3(3):423 (Abstract No. P–4–21).
   Google Scholar
• FREWER LJ, LADER M: The effects of nefazodone, imi-pramine and placebo, alone and combined with alco-hol, in normal subjects. Int. Clin. Psychopharmacol.(1993) 8:13–20.
   PubMed Web of Science ®Google Scholar